Aurinia PharmaceuticalsNASDAQ: AUPH

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia to Participate in Upcoming Investor Healthcare Conferences.

Aurinia (AUPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (Aurinia or the Company), today announced an oral presentation at the European Alliance of Associations for Rheumatology (EULAR) 2024 taking place in Vienna, Austria June 12-15. The data reinforces previous findings from the AURORA Clinical Program on the safety and effectiveness of LUPKYNIS® (voclosporin), a second generation calcineurin inhibitor (CNI), for the treatment of adult patients with act.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce.

Aurinia Pharmaceuticals (AUPH) reported a quarterly loss of $0.03 per share, which was better than the Zacks Consensus Estimate of a loss of $0.17. This is an improvement from the loss of $0.18 per share reported a year ago.

ROCKVILLE, Md. & EDMONTON, Alberta--(BUSINESS WIRE)--UPDATE: Additional information on Aurinia's presentation at the 2024 Bloom Burton & Co. Healthcare Investor Conference.

Aurinia Pharmaceuticals (AUPH) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.18 per share a year ago.

Aurinia Pharmaceuticals , the kidney therapies developer that was pushed by activist hedge fund MKT Capital to sell itself, failed to attract binding offers and will embark on share buybacks and cost cuts instead, people familiar with the matter said.

Aurinia (AUPH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.